# US 12,213,990 B2 · A3 adenosine receptor ligand for use for achieving a fat loss effect

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,213,990 B2
- Document ID: US12213990B2
- Status: Granted
- Kind: B2
- Application number: 17/309,952
- Filed: 2020-01-05
- Published: 2022-03-17
- Granted: 2025-02-04
- Earliest claimed: 2019-01-06
- Assignees: Can-Fite Biopharma Ltd.
- Applicants: Can-Fite Biopharma Ltd.
- Inventors: Motti Farbstein; Inbal Itzhak; Shira Cohen; Pnina Fishman
- Web page: https://patentgrep.com/patent/US12213990B2

## CPC

- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is an A3 adenosine receptor (A3AR) ligand for use in achieving at least one fat loss effect selected from: reducing weight of the subject; reducing body fat mass in the subject; treating obesity in the subject and inhibiting adipocytes proliferation in a subject. The disclosure also concerns pharmaceutical compositions, methods of treatment and kits comprising the A3AR ligand.

## Claims

### Claim 1

A method for treating a subject comprising administering to said subject an amount of an A3 adenosine receptor (A3AR) ligand, the amount being effective to achieve at least one fat loss effect selected from:
reduce weight of the subject;
reduce body fat mass in the subject
wherein said fat loss effect refers to reducing adipose tissues that are intended to store fat and excluding ectopic fat,
wherein said A3AR ligand inhibits adipocyte proliferation, and
wherein said A3AR ligand is CI-IB-MECA or N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine (CF602).

### Claim 2 (depends on 1)

The method according to claim 1, wherein said ligand is in a dosage form suitable for daily administration to said subject.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said dosage form is suitable for administration once or twice a day.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said ligand is in a dosage form suitable for oral administration.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said A3AR ligand is administered in combination with an anti-obesity treatment.